Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. Gonzalez-Ochoa E, et al. Among authors: bowering v. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. doi: 10.1136/ijgc-2023-004491. Int J Gynecol Cancer. 2023. PMID: 37380217 Free PMC article. Clinical Trial.
Resisting RECIST-Uniformity Versus Clinical Validity.
Wilson MK, Friedlander ML, Lheureux S, Small W Jr, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM. Wilson MK, et al. Among authors: bowering v. Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627. doi: 10.1097/IGC.0000000000001062. Int J Gynecol Cancer. 2017. PMID: 28692635
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Lheureux S, et al. Among authors: bowering v. Lancet. 2021 Jan 23;397(10271):281-292. doi: 10.1016/S0140-6736(20)32554-X. Lancet. 2021. PMID: 33485453 Free PMC article. Clinical Trial.
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Madariaga A, Mitchell SA, Pittman T, Wang L, Bowering V, Kavak N, Quintos J, Chang K, Ramsahai J, Karakasis K, Welch SA, Dhani NC, Lheureux S, Oza AM. Madariaga A, et al. Among authors: bowering v. Gynecol Oncol. 2022 Nov;167(2):226-233. doi: 10.1016/j.ygyno.2022.08.006. Epub 2022 Aug 30. Gynecol Oncol. 2022. PMID: 36055813 Free PMC article. Clinical Trial.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, Singh S, Irving M, Marsh K, Lam B, Speers V, Yosifova A, Oaknin A, Madariaga A, Dhani NC, Bowering V, Oza AM, Pugh TJ. Lheureux S, et al. Among authors: bowering v. Clin Cancer Res. 2023 Sep 15;29(18):3706-3716. doi: 10.1158/1078-0432.CCR-23-0797. Clin Cancer Res. 2023. PMID: 37327320 Free PMC article. Clinical Trial.
Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S, Bowering V, Karakasis K, Oza AM. Lheureux S, et al. Among authors: bowering v. Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8. Expert Opin Drug Saf. 2015. PMID: 26051946 Review.
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM. Lheureux S, et al. Among authors: bowering v. Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. doi: 10.1158/1078-0432.CCR-19-4121. Epub 2020 May 22. Clin Cancer Res. 2020. PMID: 32444417 Clinical Trial.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S. Madariaga A, et al. Among authors: bowering v. Nat Commun. 2023 Mar 15;14(1):1452. doi: 10.1038/s41467-023-37084-w. Nat Commun. 2023. PMID: 36922497 Free PMC article. Clinical Trial.
18 results